Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

RNA

- PMLiVE

Novo Nordisk to acquire cardiovascular disease specialist Cardior in deal worth over €1bn

The deal includes a candidate being evaluated in a mid-stage trial to treat heart failure patients

- PMLiVE

Sandoz receives FDA approval for first denosumab biosimilars Wyost and Jubbonti

The biosimilars have been authorised for all indications covered by Amgen's reference medicines

- PMLiVE

UK Biobank reveals new data from world’s largest genetic project

The data will accelerate the development of potentially lifesaving treatments and cures

- PMLiVE

New blood test to reduce heart attacks and death rates in A&E heart patients

The test could improve diagnosis for one in five patients with a heart muscle injury

- PMLiVE

Risk calculator to prevent heart attacks and strokes in type 2 diabetes patients

About one-third of adults living with diabetes die from a heart or circulatory disease

- PMLiVE

Amgen’s Wezlana receives FDA approval to treat multiple inflammatory diseases

Wezlana is approved as a biosimilar referencing Janssen Pharmaceuticals’ Stelara

- PMLiVE

Amgen presents new findings for Uplizna in neuromyelitis optica spectrum disorder

The rare and debilitating disease affects approximately one to ten per 100,000 people

- PMLiVE

EDX Medical Group develops multi-disease ‘point-of-care’ rapid tests for cancer, infections and cardiovascular conditions

The development follows the Group’s acquisition of Hutano Diagnostics

- PMLiVE

Amgen free to proceed with $27.8bn Horizon acquisition following US FTC settlement

The FTC filed an antitrust lawsuit against Amgen earlier this year in a bid to block the transaction

- PMLiVE

Alliance for Genomic Discovery announces its five founding biopharma members

The AGD aims to accelerate drug development and expand the diversity of genomic data

- PMLiVE

Amgen’s supplemental Biologics License Application for Blincyto approved by FDA

The approval for the leukaemia drug was supported by additional data from two phase 3 studies

- PMLiVE

Amgen’s Lumakras shows promise in phase 3 lung cancer study

The company has also presented results from a study of Lumakras in colorectal cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links